Using LiNGAM on 922 breast cancer patients, the study estimates that adjuvant anti-HER2 therapy lengthens the time to last recurrence-free assessment by 169 days and skin/nipple involvement shortens it by 351 days.
Title resolution pending
1 Pith paper cite this work. Polarity classification is still indexing.
1
Pith paper citing it
citation-role summary
method 1
citation-polarity summary
fields
stat.AP 1years
2025 1verdicts
REJECT 1roles
method 1polarities
use method 1representative citing papers
citing papers explorer
-
Guiding Treatment Strategies: The Role of Adjuvant Anti-Her2 Neu Therapy and Skin/Nipple Involvement in Local Recurrence-Free Survival in Breast Cancer Patients
Using LiNGAM on 922 breast cancer patients, the study estimates that adjuvant anti-HER2 therapy lengthens the time to last recurrence-free assessment by 169 days and skin/nipple involvement shortens it by 351 days.